Biotech Values

[mcbio]

I don't see anything from all this that suggests the $135m is flexible year to year.

I think the point is not that the figure you cite is flexible but that a decreasing amount of the AG, or altogether elimination of the AG, is going to translate in a higher figure of mL sales by definition, which makes it more likely that the threshold is exceeded and MNTA shifts into the profit share.